Related trials
Lopaciuk, 3000 - subcutaneous heparin vs intravenous heparin
RE-COVER, 2009 - dabigatran vs vitamin K antagonists
Romera, 2009 - Tinzaparin vs acenocoumarol
Gonz�lez-Fajardo, 2008 - Enoxaparin vs coumarin
Botticelli DVT, 2008 - apixaban vs heparin/VKA
Einstein-DVT Dose-Ranging Study, 2008 - rivaroxaban vs heparin/VKA
VanGogh DVT, 2007 - idraparinux vs heparin/VKA
VanGogh PE, 2007 - idraparinux vs heparin/VKA
Daskalopoulos, 2005 - LMWH at home vs UFH in hospital
Fiessinger , 2005 - ximelagatran vs vitamin K antagonists
Chong, 2005 - LMWH at home vs UFH in hospital
Kearon, 2004 - 4 months vs 3 months
Ramacciotti, 2004 - LMWH at home vs UFH in hospital
MATISSE, 2004 - fondaparinux vs enoxaparin
Lee, 2003 - Dalteparin vs warfarin
Agnelli, 2003 - 6-12 months vs 3 months
Kakkar, 2003 - Bemiparin vs warfarin
Deitcher, 2003 - Enoxaparin vs warfarin
MATISSE PE, 2003 - fondaparinux vs heparin/VKA
Hull, 2002 - Tinzaparin vs warfarin
Meyer, 2002 - Enoxaparin vs warfarin
Agnelli, 2001 - 12 months vs 3 months
Merli (once daily vs UFH), 2001 - once daily enoxaparin vs UFH
Lopez-Beret, 2001 - Nadroparin vs acenocoumarol
Merli, 2001 - once daily enoxaparin vs twice daily enoxaparin
See also:
All venous thrombosis clinical trials
|
|
Treatments
Studied treatment |
continuation for 3 or 9 additionnal months of warfarin or other oral anticoagulant was adjusted to achieve a target INR between 2.0 and 3.0.
|
Control treatment |
discontinuation (after 3 months)
|
Patients
Inclusion criteria |
patients ranging from 15 to 85 years of age with a first episode of symptomatic,
objectively confirmed pulmonary embolism who had completed 3 uninterrupted months of oral
anticoagulant therapy without having a recurrence of bleedingowerpo |
Exclusion criteria |
prolonged anticoagulant therapy for reasons other than venous
thromboembolism;major psychiatric disorders; life expectancy shorter than two years; |
Baseline characteristics |
time of randomization |
3 months |
|
Method and design
Randomized effectives |
NA / NA (studied vs. control) |
Design |
Parallel groups |
Blinding |
open |
Follow-up duration |
33 months |
Lost to follow-up |
NA |
Number of centre |
19 |
Geographic area |
Italy |
Primary endpoint |
Recurrence of symptomatic confirmed VTE./pj |
Results
No results available for this trial
- no clinical endpoint reported
Reference(s)
-
Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M, Imberti D, Poggio R, Ageno W, Pogliani E, Porro F, Zonzin P.
Extended oral anticoagulant therapy after a first episode of pulmonary embolism..
Ann Intern Med 2003;139:19-25
Pubmed
|
Hubmed
| Fulltext
|